<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598156</url>
  </required_header>
  <id_info>
    <org_study_id>ML19033</org_study_id>
    <secondary_id>EUDRACT 2006-002295-18</secondary_id>
    <nct_id>NCT00598156</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva</brief_title>
  <acronym>ACT</acronym>
  <official_title>Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy and bevacizumab is given for 4 months. Patients who have not progressed will
      continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab
      and erlotinib (Tarceva).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with metastatic colorectal cancer will be treated with standard chemotherapy
      according to the investigators choice. In addition to chemotherapy, Avastin (bevacizumab)
      will be given during the treatment period. After the chemotherapy is finished (after 18
      weeks), maintenance therapy will be given and the patients will be randomized to treatment
      with either with Avastin alone or Avastin in combination with Tarceva (erlotinib). Patients
      with progressive disease, or patients suitable to curative resection of metastases will be
      taken out of study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib (Tarceva)</intervention_name>
    <description>Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab (Avastin)</intervention_name>
    <description>Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adenocarcinoma of the colon or rectum.

          2. Age &gt; 18.

          3. Measurable disease according to RECIST criteria.

          4. Expected survival more than three months.

          5. Adequate bone marrow, liver and kidney function.

          6. INR &lt; 1.5 times upper limit.

          7. Adequate contraception for fertile patients.

          8. Signed written informed consent.

        Exclusion Criteria:

          1. Earlier chemotherapy for metastatic colorectal cancer.

          2. Adjuvant treatment within 6 months.

          3. Surgery or significant trauma within 28 days prior to study entry.

          4. Planned radiotherapy against target lesions.

          5. CNS metastases.

          6. Prior malignancy within 5 years except ca in situ of cervix and basal cell carcinoma.

          7. Bleeding diathesis

          8. Uncontrolled hypertension.

          9. Significant cardiovascular disease.

         10. Treatment with anticoagulant drugs.

         11. Participation in other clinical trial.

         12. Pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Johnsson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vejle Hospital, Department of Oncology</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Esbjerg Hospital</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillerod Hospital, Department of Oncology</name>
      <address>
        <city>Hillerod</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Hospital, Department of Oncology</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital, Department of Oncology</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryhov Hospital, Department of Oncology</name>
      <address>
        <city>Jonkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalmar Hospital, Department of Oncology</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital, Department of Oncology</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital MAS</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Department of Oncology</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital, Department of Oncology</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Norrland, Department of Oncology</name>
      <address>
        <city>Ume√•</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Hospital, Department of Oncology</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaxjo Hospital, Department of Oncology</name>
      <address>
        <city>Vaxjo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

